Skip to main content
SpringerLink
Log in

Antibacterial activities of nemonoxacin against clinical isolates of Staphylococcus aureus: an in vitro comparison with three fluoroquinolones

  • Original Paper
  • Published:
World Journal of Microbiology and Biotechnology Aims and scope Submit manuscript

Abstract

In comparison with ciprofloxacin, levofloxacin and moxifloxacin, antimicrobial activity of nemonoxacin against ciprofloxacin-susceptible/-resistant methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA) was determined with the availability to select resistant mutants evaluated. Minimum inhibitory concentrations and mutant prevention concentrations of quinolones were determined by agar dilution method, that concentrated bacterial cells were spread onto Mueller–Hinton agar plates containing antibacterials at different concentrations. Selection index (SI) was calculated. Minimum inhibitory concentration and mutant prevention concentration of nemonoxacin were 0.063 and 0.25 μg/mL for ciprofloxacin-susceptible MSSA and those were 0.5 and 4.0 μg/mL for ciprofloxacin-resistant MSSA, lower than observations of three fluoroquinolones distinctly. SI of nemonoxacin and moxifloxacin were similar, with narrower mutant selective window than levofloxacin and ciprofloxacin. Minimum inhibitory concentration and mutant prevention concentration of nemonoxacin were 0.25 and 2.0 μg/mL for ciprofloxacin-susceptible MRSA, which were 0.5 and 16.0 μg/mL for ciprofloxacin-resistant MRSA. Values were lower than those determined from fluoroquinolones. Nemonoxacin presents good antimicrobial activity against clinical isolates of S. aureus, especially for ciprofloxacin-resistant strains. But stepwise mutant accumulation of ciprofloxacin-resistant MRSA can be hardly inhibited by nemonoxacin with pharmacokinetic parameters considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Adam HJ, Laing NM, King CR, Lulashnyk B, Hoban DJ, Zhanel GG (2009) In vitro activity of nemonoxacin, a novel non-fluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother 53:4915–4920

    Article  CAS  Google Scholar 

  • Arjona A (2009) Nemonoxacin: quinolone antibiotic. Drug Future 34:196–203

    Article  CAS  Google Scholar 

  • Black MT, Stachyra T, Platel D et al (2008) Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases. Antimicrob Agents Chemother 52:3339–3349

    Article  CAS  Google Scholar 

  • Bradbury BJ, Pucci MJ (2008) Recent advances in bacterial topoisomerase inhibitors. Curr Opin Pharmacol 8:574–581

    Article  CAS  Google Scholar 

  • Chen S, Cui S, McDermott PF et al (2007) Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica Serovar Typhimurium to fluoroquinolones and other antimicrobials. Antimicrob Agents Chemother 51:535–542

    Article  CAS  Google Scholar 

  • Chen YH, Liu CY, Lu JJ, King CHR, Hsueh PR (2009) In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. J Antimicrob Chemother 64:1226–1229

    Article  CAS  Google Scholar 

  • Chung DT, Tsai CY, Chen SJ et al (2010) Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Antimicrob Agents Chemother 54:411–417

    Article  CAS  Google Scholar 

  • Dong Y, Zhao X, Domagala J, Drlica K (1999) Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 43:1756–1758

    CAS  Google Scholar 

  • Drlica K (2003) The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52:11–17

    Article  CAS  Google Scholar 

  • Drlica K, Zhao X, Blondeau JM, Hesje C (2006) Low correlation between minimal inhibitory concentration (MIC) and mutant prevention concentration (MPC). Antimicrob Agents Chemother 50:403–404

    Article  CAS  Google Scholar 

  • Giraud E, Baucheron S, Cloeckaert A (2006) Resistance to fluoroquinolones in Salmonella: emerging mechanisms and resistance prevention strategies. Microbes Infect 8:1937–1944

    Article  CAS  Google Scholar 

  • Gould IM, David MZ, Esposito S et al (2012) New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents 39:96–104

    Article  CAS  Google Scholar 

  • Hsu MS, Liao CH, Liu CY, Yang CJ, Huang YT, Hsueh PR (2011) In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to nemonoxacin, tigecycline, fosfomycin and other antimicrobial agents. Int J Antimicrob Agents 37:276–278

    Article  CAS  Google Scholar 

  • Kontou P, Manika K, Chatzika K et al (2013) Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. Int J Antimicrob Agents 42:262–267

    Article  CAS  Google Scholar 

  • Lai CC, Tan CK, Lin SH et al (2009) Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species. J Antimicrob Chemother 64:73–78

    Article  CAS  Google Scholar 

  • Lai CC, Liu WL, Ko WC et al (2011) Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various nocardia species. Antimicrob Agents Chemother 55:2084–2091

    Article  CAS  Google Scholar 

  • Lauderdale TL, Shiau YR, Lai JF, Chen HC, King CHR (2010) Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. Antimicrob Agents Chemother 54:1338–1342

    Article  CAS  Google Scholar 

  • Li CR, Li Y, Li GQ et al (2010) In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone. J Antimicrob Chemother dkq341

  • Odenholt I, Löwdin E, Cars O (2003) Postantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacin. Antimicrob Agents Chemother 47:3352–3356

    Article  CAS  Google Scholar 

  • Paphitou NI (2013) Antimicrobial resistance: action to combat the rising microbial challenges. Int J Antimicrob Agents 42(Suppl 1):S25–S28

    Article  CAS  Google Scholar 

  • Stass H, Dalhoff A, Kubitza D, Schühly U (1998) Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subject. Antimicrob Agents Chemother 42:2060–2065

    CAS  Google Scholar 

  • Tan CK, Lai CC, Liao CH et al (2009) Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 64:428–429

    Article  CAS  Google Scholar 

  • Tang X, Huang Y, Wen Q, Liu Z (2005) Bioequivalence of ciprofloxacin tablets in healthy volunteers. Chin Pharmacol Bull 21:1116–1119 (in Chinese)

    Google Scholar 

  • Theuretzbacher U (2011) Resistance drives antibacterial drug development. Curr Opin Pharmacol 11:433–438

    Article  CAS  Google Scholar 

  • Trucksis M, Hooper DC, Wolfson JS (1991) Emerging resistance to fluoroquinolones in staphylococci: an alert. Ann Intern Med 114:424–426

    Article  CAS  Google Scholar 

  • Turkmani A, Psaroulaki A, Christidou A, Chochlakis D, Tabaa D, Tselentis Y (2008) In vitro-selected resistance to fluoroquinolones in two Brucella strains associated with mutational changes in gyrA. Int J Antimicrob Agents 32:227–232

    Article  CAS  Google Scholar 

  • van Rensburg DJ, Perng RP, Mitha IH et al (2010) Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. Antimicrob Agents Chemother 54:4098–4106

    Article  Google Scholar 

  • Zhang L, Li J, Lv Y et al (2001) Pharmacokinetic study of levofloxacin in Chinese healthy volunteers. Chin Pharm J 36:834–837 (in Chinese)

    Google Scholar 

  • Zhao X, Drlica K (2001) Restricting the selection of antibiotic -resistant mutant bacteria: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 33(Suppl3):S147–S156

    Article  CAS  Google Scholar 

  • Zhao X, Eisner W, Perl-Rosenthal N, Kreiswirth B, Drlica K (2003) Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother 47:1023–1027

    Article  Google Scholar 

  • Zhou J, Dong Y, Zhao X et al (2000) Selection of antibiotic resistance: allelic diversity among fluoroquinolone-resistant mutations. J Infect Dis 182:517–525

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The authors showed great gratitude to the staff from Department of Respiratory Diseases, People’s Liberation Army General Hospital and Department of Respiratory Diseases, Second Artillery General Hospital.

Author information

Authors and Affiliations

  1. Department of Respiratory Diseases, The Second Artillery General Hospital, Beijing, 100088, People’s Republic of China

    Zhaoxia Li

  2. Department of Respiratory Diseases, PLA General Hospital, Beijing, 100853, People’s Republic of China

    Youning Liu & Aimin Li

  3. Department of Clinical Pharmacology, PLA General Hospital, Beijing, 100853, People’s Republic of China

    Rui Wang

Authors
  1. Zhaoxia Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Youning Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rui Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aimin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Youning Liu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Z., Liu, Y., Wang, R. et al. Antibacterial activities of nemonoxacin against clinical isolates of Staphylococcus aureus: an in vitro comparison with three fluoroquinolones. World J Microbiol Biotechnol 30, 2927–2932 (2014). https://doi.org/10.1007/s11274-014-1720-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11274-014-1720-2

Keywords

Search

Navigation